WO2021058795A3 - Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof - Google Patents

Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof Download PDF

Info

Publication number
WO2021058795A3
WO2021058795A3 PCT/EP2020/076995 EP2020076995W WO2021058795A3 WO 2021058795 A3 WO2021058795 A3 WO 2021058795A3 EP 2020076995 W EP2020076995 W EP 2020076995W WO 2021058795 A3 WO2021058795 A3 WO 2021058795A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding domains
antibodies
same
senescent cell
chimeric antigen
Prior art date
Application number
PCT/EP2020/076995
Other languages
French (fr)
Other versions
WO2021058795A2 (en
Inventor
Müge OGRUNC
Thierry MATHIEU
Original Assignee
Stark Labs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/585,256 external-priority patent/US20210093665A1/en
Application filed by Stark Labs filed Critical Stark Labs
Priority to CA3155930A priority Critical patent/CA3155930A1/en
Priority to EP20789003.9A priority patent/EP4034561A2/en
Publication of WO2021058795A2 publication Critical patent/WO2021058795A2/en
Publication of WO2021058795A3 publication Critical patent/WO2021058795A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464458—Proteinases
    • A61K39/46446—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464463—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to DEP1-binding domains and DPP4-binding domains, as well as antibodies and chimeric antigen receptors (CAR) comprising the same. Also disclosed are uses and methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells.
PCT/EP2020/076995 2019-09-27 2020-09-25 Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof WO2021058795A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3155930A CA3155930A1 (en) 2019-09-27 2020-09-25 Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
EP20789003.9A EP4034561A2 (en) 2019-09-27 2020-09-25 Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19200182.4 2019-09-27
US16/585,256 US20210093665A1 (en) 2019-09-27 2019-09-27 Chimeric antigen receptors against senescent cells and uses thereof
EP19200182 2019-09-27
US16/585,256 2019-09-27

Publications (2)

Publication Number Publication Date
WO2021058795A2 WO2021058795A2 (en) 2021-04-01
WO2021058795A3 true WO2021058795A3 (en) 2021-05-27

Family

ID=72811789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/076995 WO2021058795A2 (en) 2019-09-27 2020-09-25 Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof

Country Status (3)

Country Link
EP (1) EP4034561A2 (en)
CA (1) CA3155930A1 (en)
WO (1) WO2021058795A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805587B (en) * 2022-06-10 2023-11-28 清华大学 CAR-NK cells and their use in the treatment of organ and tissue aging and fibrosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064750A2 (en) * 2000-03-01 2001-09-07 Vanderbilt University Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
WO2005118643A2 (en) * 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of cd148
WO2007014169A2 (en) * 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
EP3029069A1 (en) * 2013-07-31 2016-06-08 Juntendo Educational Foundation Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof
WO2018027197A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
WO2018160768A1 (en) * 2017-02-28 2018-09-07 Vor Biopharma, Inc. Compositions and methods for inhibition lineage specific proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ATE373078T1 (en) 2000-02-24 2007-09-15 Xcyte Therapies Inc SIMULTANEOUS STIMULATION AND CONCENTRATION OF CELLS
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US8703485B2 (en) 2007-06-01 2014-04-22 Omt, Inc. Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064750A2 (en) * 2000-03-01 2001-09-07 Vanderbilt University Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
WO2005118643A2 (en) * 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of cd148
WO2007014169A2 (en) * 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
EP3029069A1 (en) * 2013-07-31 2016-06-08 Juntendo Educational Foundation Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof
WO2018027197A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
WO2018160768A1 (en) * 2017-02-28 2018-09-07 Vor Biopharma, Inc. Compositions and methods for inhibition lineage specific proteins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALINA SOARE ET AL: "Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis", ARTHRITIS & RHEUMATOLOGY (HOBOKEN), vol. 72, no. 1, 26 July 2019 (2019-07-26), US, pages 137 - 149, XP055763586, ISSN: 2326-5191, DOI: 10.1002/art.41058 *
KYOUNG MI KIM ET AL: "Identification of senescent cell surface targetable protein DPP4", GENES AND DEVELOPMENT., vol. 31, no. 15, 1 August 2017 (2017-08-01), US, pages 1529 - 1534, XP055675992, ISSN: 0890-9369, DOI: 10.1101/gad.302570.117 *
M ALTHUBITI ET AL: "Characterization of novel markers of senescence and their prognostic potential in cancer", CELL DEATH AND DISEASE, vol. 5, no. 11, 20 November 2014 (2014-11-20), pages e1528, XP055203343, DOI: 10.1038/cddis.2014.489 *
MYRIANTHOPOULOS VASSILIOS ET AL: "Senescence and senotherapeutics: a new field in cancer therapy", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 193, 16 August 2018 (2018-08-16), pages 31 - 49, XP085563807, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2018.08.006 *
TAKAHASHI TAKAMUNE ET AL: "A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 4, 15 August 2006 (2006-08-15), pages 1234 - 1242, XP086510140, ISSN: 0006-4971, [retrieved on 20201104], DOI: 10.1182/BLOOD-2005-10-4296 *
TANGYE S G ET AL: "CD148: a receptor-type protein tyrosine phosphatase involved in the regulation of human T cell activation", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 161, no. 7, 1 October 1998 (1998-10-01), pages 3249 - 3255, XP002174298, ISSN: 0022-1767 *
YOTIS SENIS ET AL: "Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?", MOLECULES, vol. 23, no. 3, 2 March 2018 (2018-03-02), pages 1 - 16, XP055694810, DOI: 10.3390/molecules23030569 *

Also Published As

Publication number Publication date
EP4034561A2 (en) 2022-08-03
CA3155930A1 (en) 2021-04-01
WO2021058795A2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
EP4286415A3 (en) Humanized antigen-binding domains against cd19 and methods of use
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
WO2017156500A8 (en) TGFβ1-BINDING IMMUNOGLOBULINS AND USE THEREOF
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
PH12019502356A1 (en) Trem2 antigen binding proteins and uses thereof
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
WO2018170351A8 (en) Anti-phf-tau antibodies and uses thereof
WO2019224711A3 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
WO2016191643A4 (en) Tigit-binding agents and uses thereof
MX2019007848A (en) Anti-pd-1 antibodies and uses thereof.
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
JOP20190002A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
NZ715896A (en) Humanized or chimeric cd3 antibodies
UA103499C2 (en) Antibody against human il17 and uses thereof
WO2010102276A3 (en) Humanized anti-cd19 antibody formulations
MX2020008736A (en) B7-h4 antibody formulations.
WO2021097223A3 (en) Biparatopic cd73 antibodies
WO2019112347A3 (en) Antibody or antigen binding fragment thereof for specifically recognizing b cell malignancy, chimeric antigen receptor comprising same, and use thereof
MY193821A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
WO2015157238A3 (en) Binding molecules specific for il-21 and uses thereof
SG10201801219VA (en) Anti-HER2 Antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20789003

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3155930

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2020789003

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2020789003

Country of ref document: EP

Effective date: 20220428